Traditional phase 1 and 2 studies in thoracic radiation oncology should be abandoned

International Journal of Radiation Oncology Biology Physics

Volumn 90, Issue 3, 2014, Pages 487-489

  Faivre Finn, Corinne ^a   Snee, Michael ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b St James's Institute of Oncology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; PACLITAXEL; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVANCED CANCER; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; CONSOLIDATION CHEMOTHERAPY; HUMAN; NON SMALL CELL LUNG CANCER; NOTE; ONCOLOGY; ORGANS AT RISK; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIATION DOSE; RADIATION DOSE ESCALATION; RADIATION INJURY; STUDY DESIGN; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT DURATION; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; METHODOLOGY; MORTALITY; PROCEDURES; RADIATION RESPONSE; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LUNG NEOPLASMS; ORGANS AT RISK; RESEARCH DESIGN; TREATMENT FAILURE;

EID: 84907997792     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.05.044     Document Type: Editorial

References (10)

1. M. Machtay, R. Paulus, and J. Moughan Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma: A Radiation Therapy Oncology Group analysis J Thorac Oncol 7 2012 716 722
2. M. Christodoulou, N. Bayman, and P. McCloskey New radiotherapy approaches in locally advanced non-small cell lung cancer Eur J Cancer 3 2014 525 534
3. J.D. Bradley, K. Bae, and M.V. Graham Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small-cell lung cancer: RTOG 0117 J Clin Oncol 28 2010 2475 2480
4. J.D. Bradley, R. Paulus, and R. Komaki A randomized phase III comparison of standard dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: results on radiation dose in RTOG 0617 J Clin Oncol 31 2013 7501
5. J.D. Bradley, G.S. Masters, and C. Hu An intergroup randomized phase III comparison of standard dose (60 Gy) versus high dose (74 Gy) chemoradiotherapy (CRT) +/- cetuximab (Cetux) for stage III non small cell lung cancer (NSCLC): results on cetux from RTOG 0617 J Thor Oncol 8 2013 S3 [abstract]
6. M. Werner-Wasik, R. Paulus, and W.J. Curran Jr. Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: Analysis of the radiation therapy oncology group (RTOG) database Clin Lung Cancer 12 2011 245 251
7. D. Palma, S. Senan, and C. Oberije Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: An individual patient data meta-analysis Int J Radiat Oncol Biol Phys 87 2013 690 696
8. D.A. Palma, S. Senan, and K. Tsujino Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: An international individual patient data meta-analysis Int J Radiat Oncol Biol Phys 85 2013 444 450
9. D.M. Cannon, M.P. Mehta, and J.B. Adkison Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer J Clin Oncol 31 2013 4343 4348
10. P. Koh, C. Faivre-Finn, and F. Blackhall Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy Cancer Treat Rev 38 2012 626 640